NCT01364662View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

PHASE2CompletedINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

Impulsive Aggression Comorbid With ADHD

Interventions

DRUG

SPN-810

administered orally

DRUG

Placebo

administered orally

Trial Locations (27)

Unknown

Dothan

Los Angeles

Santa Ana

Washington D.C.

Bradenton

Gainesville

Hialeah

Jacksonville

Maitland

North Miami

Orlando

Tampa

Atlanta

Libertyville

Indianapolis

Terre Haute

Owensboro

Toms River

Stony Brook

Cleveland

Columbus

Philadelphia

Pittsburgh

Charleston

Memphis

Bellevue

Bothell

All Listed Sponsors

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT01364662 - A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter